Solutions
Advisory Services
Clinical Development
- Generics Development
- Clinical Operations
- Clinical Data Sciences
- Medical and Safety Services
- RWD & RWE Services
Post Marketing
- Safety Services
- Post marketing Studies
- Regulatory Affairs
The inaugural Consumer Healthcare (CHC) Safety Roundtable, hosted by Navitas pvnetworks and led by industry leaders Dr. Latika Sharma, MBBS, MD, Ben Parsons, and Dr. Sara Hall, PhD, served as a pivotal gathering for discussing the evolving landscape of consumer healthcare product safety. In this exclusive event, distinguished industry experts, Viny...
As the world observes World Parkinson’s Day on April 11th, a day dedicated to raising awareness about Parkinson’s disease and honouring Dr. James Parkinson, who first described the condition in 1817, the spotlight turns to groundbreaking initiatives that harness genetic research to transform patient care. One such initiative, PD GENEr...
On April 7, 2025, we join the World Health Organisation, under the banner of Healthy beginnings, hopeful futures. The World Health Day 2025 campaign urges stakeholders to take decisive action against preventable maternal and newborn deaths. Over 300,000 women lose their lives annually due to pregnancy or childbirth, and 4 million newborns die or ar...
The pharmaceutical industry is experiencing a paradigm shift in medical writing, driven by artificial intelligence (AI), structured content authoring, and automation. Navitas Life Sciences’ 3rd Medical Writing Roundtable, hosted by Dr Latika Sharma and Dr. Sara Giadrossi, brought together industry leaders from 10+ global pharmaceutical compa...
The pharmaceutical industry is undergoing a significant transformation driven by digital innovation and artificial intelligence (AI). It has become increasingly beneficial to leverage AI powered tools and cloud based regulatory solutions to streamline regulatory submissions. These advancements enhance efficiency, improve data exchange, and ensure c...
The global generics market is on an accelerated growth path, with the U.S. leading the way, projected to surpass USD 508.37 billion by 2034 at a CAGR of 12.00%. This momentum is driven by rising healthcare costs, expiring patents, and increasing regulatory support for generic drug approvals. However, growth brings complexity. Regulatory scrutiny is...
Ensuring Compliance with the Windsor Framework The Windsor Framework is now implemented, transforming the regulatory landscape for pharmaceutical companies operating in the UK. While the framework simplifies processes by enabling a UK-wide licensing system under the Medicines and Healthcare products Regulatory Agency (MHRA), companies that have not...
Phase 1 clinical trials are the foundation of clinical drug development, marking the transition from laboratory research to human testing. These first-in-human trials are designed to evaluate the safety, dosage, and pharmacokinetics of investigational drugs in a small group of healthy volunteers or patients. The insights gained at this stage are cr...
In January 2025, we were honoured with the EcoVadis Bronze Medal for our sustainability initiatives. This recognition affirms our dedication to sustainability and strengthens our position as a leading CRO that integrates responsible business practices into every aspect of clinical trials. "We take great pride in integrating ESG principles into our ...
Every year, February 11 marks the International Day of Women and Girls in Science, a day dedicated to recognizing the contributions of women in science, technology, engineering, and mathematics (STEM). The Gender Gap in Science: Challenges and Progress Despite the groundbreaking work of female scientists like Marie Curie, Rosalind Franklin, and Tu ...